com701
Endometrial Neoplasms
Compugen LtdPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
45 Active assets in the Endometrial Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisotumab Vedotin Seagen Inc. | Phase 2 | BBB |
LENVATINIB Merck Sharp & Dohme LLC | Phase 3 | BB |
Pembrolizumab Eli Lilly and Company | Phase 3 | BB |
Carboplatin Eli Lilly and Company | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Eli Lilly and Company | Phase 3 | BB |
View all 50 →
Same molecule, other indications
com701 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →